Marker Therapeutics

Marker Therapeutics is a company that provides clinical-stage immuno-oncology immunotherapies. The company was founded in 2018, in Houston, Texas, United States.

The company offers T-cell based treatment options for hematological malignancies and solid tumor indications. Their cell therapy technology is based on the selective expansion of non-engineered, and tumor specific T-cells that target specific antigens related to a tumor and kill those related tumor cells. When introduced into the patient, the T-cells attack multiple targets in order to activate an immune system response and produce a broad spectrum of anti-tumor activities.

Marker Therapeutics looks to eventually create treatments for the purpose of fighting lymphoma, multiple myeloma, solid tumors, acute myeloid leukemia, as well as acute lymphoblastic leukemia. They are also pursuing post-transplant treatments against acute myeloid leukemia with their MultiTAA program.

Their MultiTAA therapy is in Phase 2 of clinical trials and is being evaluated for the treatment of breast cancer, lymphoma, multiple myeloma, pancreatic cancer, and sarcoma.